AccuMetab™ Human CYP17A1 Enzyme, Catalytically Active with Cytochrome b5

CAT#: ITS-0426-YL78
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Enhanced human CYP17A1 for high-activity Phase I metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Supplementing the dual-functioning CYP17A1 enzyme with Cytochrome b5 pushes its steroidogenic activity to peak physiological levels. This format is the gold-standard for rigorously testing the efficacy of next-generation oncology inhibitors and endocrine modulators.
Key Features
Cytochrome b5 pushes steroidogenesis to peak capacity; Ultimate screen for novel prostate cancer inhibitors; Eliminates background noise of crude tissue assays; High-reductase expression for endocrine disruption screening
Applications
Enhanced Drug Metabolism Studies, MetID, DDI
Research Areas
ADME; Oncology; Endocrinology
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry